A Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs TgDCC E1A gene therapy (Primary) ; Paclitaxel
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.